ImmuPharma
Private Company
Funding information not available
Overview
ImmuPharma is a clinical-stage biotech focused on developing curative therapies for autoimmune diseases and innovative solutions for diabetes management. Its core technology is the P140 (Lupuzor) peptide, a first-in-class 'immunormalizer' designed to address the root cause of autoimmunity by modulating the chaperone-mediated autophagy pathway. The company is also advancing Kapiglucagon, a stable glucagon prodrug for next-generation artificial pancreas technology. With a leadership team combining scientific, clinical, and financial expertise, ImmuPharma aims to shift the treatment paradigm from symptom management to disease modification.
Technology Platform
Peptide-based 'immunormalizer' platform targeting chaperone-mediated autophagy (CMA) for autoimmune diseases, and prodrug engineering platform for hormone stabilization (e.g., glucagon).
Opportunities
Risk Factors
Competitive Landscape
In autoimmune diseases, ImmuPharma faces competition from large pharma and biotech firms with extensive biologic and small molecule portfolios. Its differentiation is a potential curative approach versus chronic management. In diabetes tech, it competes with other stable glucagon developers and must integrate its solution into complex device ecosystems dominated by large medtech players.